Long-term follow-up for HPV vaccine study participants
Part of Infections clinical trials.
This study checks the long-term safety and effectiveness of the HPV vaccine (Gardasil 9) in people who received one or two doses in an earlier study. It aims to see how well the vaccine continues to protect against HPV-related conditions over many years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the original ESCUDDO study and received one or two doses of the HPV vaccine (Gardasil 9).
- You can attend a total of three study visits.
- You are between 21 and 26 years old at the time of your 9.5-year study visit.
- You are not pregnant.
- You have not received an HPV vaccine since the original study.
- You can provide an identification document.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if one dose of the 9-valent HPV vaccine given at ages 9-11 still protects you 6 years later. It is for people who only had that single dose and no other HPV shots.
This study tests how HPV antibodies work in urine samples from women with HPV16 before and after they get the HPV vaccine (Gardasil 9). It helps researchers understand how the vaccine protects against HPV.
This study checks how well the HPV (cancer-preventing) vaccine protection stays in your body over time. It may help confirm the vaccine’s “long-lasting” immune response and guide future vaccination confidence.
This study checks how well two types of domestic HPV vaccines and one imported HPV vaccine boost your immune system. It is for girls aged 13-14 who have already finished their HPV vaccine shots about a month ago.
This study tests a 9-valent HPV vaccine (protects against 9 types of human papillomavirus) in women who have already completed a previous HPV vaccine series. Researchers will check how safe the new vaccine is and how well your immune system responds to it.
This trial tests whether getting the HPV vaccine after treatment for vulvar high-grade lesions can help prevent the lesions from coming back. It is for women who have not been vaccinated before and are about to have treatment for this condition.
Hear when a new Human Papillomavirus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.